Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program
Abstract Background The incidence of Merkel cell carcinoma (MCC), a rare form of skin cancer with a poor prognosis, has increased in Italy in recent decades. Avelumab, an anti-programmed death ligand 1 monoclonal antibody, is approved for the treatment of metastatic MCC (mMCC) based on the results o...
Main Authors: | Giovanni Grignani, Vanna Chiarion Sileni, Carmine Pinto, Roberta Depenni, Nicola Fazio, Luca Galli, Dario Giuffrida, Carlo Carnaghi, Domenico Ciliberto, Domenico C. Corsi, Paola Queirolo, Elena Benincasa, Filippo Venturini, Gennaro Fazzi, Nuno Costa, Paolo Antonio Ascierto |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-02-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-021-02730-8 |
Similar Items
-
Immunotherapy in Merkel cell carcinoma: role of Avelumab
by: Palla AR, et al.
Published: (2018-03-01) -
Favorable Response to Treatment with Avelumab in an HIV-Positive Patient with Advanced Merkel Cell Carcinoma Previously Refractory to Chemotherapy
by: Mohammed U. Al Homsi, et al.
Published: (2018-07-01) -
Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma
by: Luciana Buonerba, et al.
Published: (2020-10-01) -
Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma
by: Sandy Tun Min, et al.
Published: (2019-08-01) -
Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe
by: Kate Fife, et al.
Published: (2021-05-01)